💊💉 #avelumab
SmPC for Bavencio 20 mg/mL concentrate for solution for infusion has been updated with changes to sections 4.2 Posology and method of administration; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 5.2 Pharmacokinetic properties; 10. Date of revision of the text on 04/2023.
🌐 https://www.medicines.org.uk/emc/product/8453/smpc
Change log: https://www.medicines.org.uk/emc/product/8453/smpc/history
💊💉 #avelumab
SmPC for Bavencio 20 mg/mL concentrate for solution for infusion has been updated with changes to sections 6.3 Shelf life; 10. Date of revision of the text on 03/2023.
🌐 https://www.medicines.org.uk/emc/product/8453/smpc
Change log: https://www.medicines.org.uk/emc/product/8453/smpc/history
Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons
#talazoparib #avelumab #solidtumors
Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy
#talazoparib #avelumab #solidtumors